How to Use AOM 400 Maintenance Treatment in Bipolar I Disorder
How should clinicians implement and monitor aripiprazole once-monthly 400 mg maintenance treatment in Black/African American adults with bipolar I disorder who are already stabilized on aripiprazole?
Clinicians treating bipolar I disorder may need practical guidance on whether and how to continue long-acting injectable aripiprazole in Black/African American patients, a population historically underrepresented in second-generation LAI trials. This guide applies to maintenance treatment after prior aripiprazole stabilization and focuses on the stability criteria, dosing schedule, and monitoring domains described in the article.
-
Confirm that the patient fits the maintenance-treatment population studied
Use this approach for adults with bipolar I disorder who have already been stabilized on aripiprazole before entering maintenance treatment. In the study, de novo participants were outpatients aged 18 to 65 years with DSM-IV-TR bipolar I disorder confirmed by the Mini-International Neuropsychiatric Interview and a history of at least 1 previous manic or mixed episode requiring hospitalization or treatment with a mood stabilizer or antipsychotic. The de novo cohort excluded patients with a current depressive episode or 9 or more episodes in the past year.
-
Administer AOM 400 on the studied maintenance schedule
During the maintenance phase, give aripiprazole once-monthly 400 mg as a single gluteal intramuscular injection every 4 weeks. In the extension study, treatment continued for up to 52 weeks, although some rollover patients had a reduced open-label phase of 28 weeks because of a protocol amendment. The article notes that fewer Black/African American patients than White or Asian participants received a reduced dose of 300 mg, indicating that the lower adverse-event burden in this subgroup was not attributable to more frequent dose reduction.
-
Assess clinical stability using the study definition
At baseline and follow-up, define stability using the same 4-part framework used in the study: outpatient status, Young Mania Rating Scale total score of 12 or lower, Montgomery-Asberg Depression Rating Scale total score of 12 or lower, and no active suicidality. Active suicidality was defined as a MADRS item 10 score of 4 or higher, or a yes response on question 4 or 5 of the Columbia-Suicide Severity Rating Scale. This stability definition is central to interpreting the maintenance results, including the finding that 90.1% of Black/African American patients who were stable at baseline remained stable at the last visit.
-
Monitor manic, depressive, and global severity symptoms longitudinally
Track YMRS, MADRS, and CGI-BP-S scores over the maintenance period. In the study, YMRS showed small improvement from baseline to week 52 and MADRS and CGI-BP-S scores remained largely unchanged across racial groups, a pattern interpreted as maintenance of stability rather than acute symptom reduction. Expect minimal change if the patient is already stabilized before LAI maintenance begins.
-
Monitor tolerability with emphasis on TEAEs, EPS, weight, and metabolic measures
Follow treatment-emergent adverse events with specific attention to extrapyramidal symptoms, weight gain, and metabolic parameters. The study assessed clinician-rated EPS using the Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale, and Simpson-Angus Scale, and changes on these scales were minimal and not clinically meaningful across racial groups. Weight gain of 7% or more from baseline occurred in 16.3% of Black/African American patients, and potentially clinically relevant fasting triglyceride values occurred in 29.2% of those with available data.
-
Include functioning and quality-of-life measures in follow-up
Assess functioning with the FAST questionnaire and quality of life with the Brief QoL.BD when following patients on maintenance AOM 400. In Black/African American patients, the least squares mean FAST total score change from baseline to week 52 was -5.97, and improvement in FAST correlated with improvement in YMRS and MADRS scores. These data support looking beyond relapse prevention alone when discussing maintenance benefit.
-
Interpret discontinuation carefully and evaluate substance-use-related barriers
If treatment is interrupted or discontinued, distinguish adverse-event discontinuation from protocol or behavioral causes. In this analysis, all-cause discontinuation was higher in Black/African American patients at 51.0%, but much of this difference was driven by protocol-specified withdrawal criteria, with 15 of 18 such withdrawals following a positive drug test. The article notes that comorbid substance use can add clinical complexity and may be relevant when considering LAIs because of their potential to support adherence.
-
Use shared decision-making when discussing LAI treatment
Discuss AOM 400 as a maintenance option within a shared decision-making framework rather than relying on race-based assumptions about efficacy or tolerability. The authors state that clinicians should assess patients individually and consider newer second-generation antipsychotics such as AOM 400 wherever possible, in line with current guideline-supported use of SGAs for bipolar disorder. The article also highlights barriers that may affect uptake, including mistrust, inequities in care access, reimbursement issues, and limited infrastructure for LAI use.
Clinical Considerations
- These findings apply to maintenance treatment in patients already stabilized on aripiprazole and likely enriched for responders and tolerators, not to acute de novo treatment decisions.
- This was an exploratory post hoc analysis of an open-label study, and inferential statistics were nominal and hypothesis-generating rather than confirmatory.
- Most Black/African American participants were enrolled in North America, so regional and healthcare-system factors may confound race-based comparisons.
- Metabolic conclusions are limited because HbA1c, glucose, and most lipid data were too sparse for meaningful race-specific analysis.
Bottom Line
For Black/African American adults with bipolar I disorder who are already stable on aripiprazole, AOM 400 can be used every 4 weeks as maintenance treatment while monitoring stability, EPS, weight, metabolic signals, functioning, and quality of life.
